


# COVAX supply outlook

Aurelia Nguyen, Managing Director COVAX Facility

---

6 July 2021



# Following supply shortages COVAX is responding to increase supply and mitigate risks

## Challenges

- COVID vaccines have been developed, approved and manufactured at a speed and scale that is unprecedented. The complexity and scale of the task, means global supply challenges occurred impacting many countries and COVAX
- COVAX's supply challenges with several vaccines have been due to delays in concluding clinical trials, regulatory approval, and validation of new sites, manufacturing scale up issues, supply chain bottlenecks, export controls.
- COVAX has recognised the need to mitigate these risks in future by a diversified portfolio of vaccines, produced from different manufacturing sites across the globe, and to actively manage the portfolio
- We expect Q4 supply will increase as more vaccines receive WHO EUL, more doses are produced due to manufacturing scale up and exports begin to normalise and expected restart of supplies from India. However, this is dependent on the regulatory approvals of new vaccines coming on time, production sites receiving approvals, and successful manufacturing scale up especially with new biotech companies.

## Increasing the Portfolio

- **DOSE SHARING:** To boost immediate availability of vaccines, **countries with surplus vaccines have already committed to sharing an additional 530+ million doses**, with deliveries from France and New Zealand already underway. COVAX is seeking clarity on remaining donations announced at the G7 Summit.
- **PORTFOLIO DIVERSIFICATION:** Continuing its active portfolio management, **COVAX has signed APAs with four new manufacturers for up to nearly 1.5 billion doses:** Moderna (500M), Novavax (350M), J&J (200M) and Clover (414m). These deals secure substantial volumes for 2021-22 supply and help COVAX to further diversify its portfolio in terms of geography, vaccine technologies and manufacturing footprint.


## Future Solutions

- **MANUFACTURING TASKFORCE:** We are working to increase manufacturing, including new and sustainable capacity in Lower Middle Income Countries (LMIC).
- **OWNERSHIP TRANSFER:** We are considering dose ownership transfer models like reselling, market place and exchange that could alleviate mismatches in supply and demand and mitigate risk.

# COVAX Facility candidate-specific supply

**PRELIMINARY AND SUBJECT TO ASSUMPTIONS**

## COVAX Available Supply, M doses, 2021 and 2022



There are currently nine vaccines in the COVAX portfolio:

1. SII: Covishield ("AZD1222")
2. SII: Covovax ("NVX-CoV2373")
3. Moderna: mRNA 1273
4. Novavax : NVX-CoV2373
5. Janssen J&J<sup>2</sup>: Ad26COV2.S
6. AstraZeneca: ChAdOx1-S [recombinant] ("AZD1222")
7. Pfizer/BioNTech: BNT162b2
8. Sanofi-GSK: Recombinant Protein
9. Clover Biopharmaceuticals: SCB-2019

1 "Committed doses" are doses that the COVAX Facility is required to procure. "Optional doses" are doses that the COVAX Facility has the option to procure in the future, but is not required to purchase. Once optional doses are exercised, they become committed doses. For non-binding agreements and deals under active negotiation, the split of committed vs. optional doses will be finalized upon deal signature.

2 COVAX has signed an Advance Purchase Agreement (APA) with Janssen for 200M doses; negotiations for an additional 300M doses are ongoing as per the Memorandum of Understanding [announced](#) on 18 December 2020.

3 "Dose donations" are estimated based upon commitments from donors to share new doses with the COVAX Facility. The transfer of COVAX allocations between COVAX Facility Participants from SFPs to AMC Participants are already included in the volumes secured by COVAX from legally-binding agreements.

4 US support has allowed COVAX to secure an additional 500M Pfizer/BioNTech doses. Reflecting US funding above its original pledge, 200M of these are recorded as a donation.

5 In the following supply forecast slides, volumes for expected single-dose regimen candidates have been doubled to ensure comparability with two-dose candidates.

# COVAX Facility global supply forecast

By AMC-eligible and Self-Financing Participants

**PRELIMINARY AND SUBJECT TO ASSUMPTIONS**

Last updated 28 June. Does not include Clover

## CAVEATS

**Contracts:** Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

**Candidate attrition:** Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

**Regulatory approval:** Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

**Manufacturing:** In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.


**Delivery:** Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

**Funding availability:** Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

**Allocation:** These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

## COVAX Available Supply, Cumulative, M doses, 2021 and 2022<sup>1</sup>

■ AMC ■ Max. SFP volume<sup>2</sup> □ Confirmed dose donations<sup>3</sup>



<sup>1</sup> Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.  
<sup>2</sup> Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.  
<sup>3</sup> “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes. Total donations on this chart are larger than 515M due to doubling of single-dose candidates.